JONATHAN M DAVIS, M.D.
Medical Practice in Boston, MA

2007015, Jul 5, 2007

Dec 29, 2006

11/648505

Michael Super - Lexington MA, US
Jonathan Davis - Auburndale MA, US
Pascal Stein - Boston MA, US

Merck Patent GmbH - Darmstadt

A61K 39/395, C07K 16/44

424133100, 530388100

Anti-CD19 B4 antibodies with modified variable regions are disclosed. The modified anti-CD19 variable region polypeptides have alterations to one or more framework regions or complementarity determining regions of the heavy chain variable region or light chain variable region, thereby to reduce a T-cell response.

2007028, Dec 13, 2007

Mar 23, 2007

11/728048

Jonathan Davis - Auburndale MA, US
James Huston - Newton Lower Falls MA, US

Merck Patent GmbH - Darmstadt

C12P 21/00, C07H 21/00, C07K 14/00, C07K 16/00, C12N 1/00

435069100, 435243000, 530350000, 530387100, 530402000, 536023100

The present invention provides an engineered multidomain protein including at least two nonidentical engineered domains, each of which contains a protein-protein interaction interface containing amino acid sequence segments derived from two or more existing homologous parent domains, thereby conferring on the engineered domains assembly specificities distinct from assembly specificities of the parent domains. In particular, the engineered domains form heterodimers with one another preferentially over forming homodimers. Methods of designing and using the engineered proteins are also included.

8420098, Apr 16, 2013

Apr 13, 2011

13/085864

Ray Camphausen - Wayland MA, US
Jonathan H. Davis - Auburndale MA, US
Sharon T. Cload - Cambridge MA, US
Fabienne M. Denhez - Arlington MA, US
Dasa Lipovsek - Cambridge MA, US
Ching-Hsiung Frederick Lo - Pennington NJ, US
Chee Meng Low - Allston MA, US
Bowman Miao - Churchville PA, US
Tracy S. Mitchell - Billerica MA, US
Rex A. Parker - Titusville NJ, US
Ginger C. Rakestraw - Cambridge MA, US
Katie A. Russo - Watertown MA, US
Doree F. Sitkoff - Dresher PA, US

Bristol-Myers Squibb Company - Princeton NJ

A61K 39/00, C07K 1/00

4241851, 530382

The present invention relates to fibronectin based scaffold domain proteins that bind PCSK9. The invention also relates to the use of the innovative proteins in therapeutic applications to treat atherosclerosis, hypercholesterolemia and other cholesterol related diseases. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative protein.

2010002, Feb 4, 2010

Apr 24, 2009

12/429930

Jonathan H. Davis - Auburndale MA, US

Merck Patent GmbH - Darmstadt

C40B 30/04, C07K 14/00, C40B 40/10, C40B 40/06, C07H 21/04, C12N 1/20

506 9, 530324, 506 18, 506 16, 536 231, 4352523

The present invention provides proteins having one or more similarities to the artificial protein Top7 or to a Top7 derivative. Proteins of the invention have one or more loops that are longer than the corresponding loops of Top7, and/or that bind to a preselected target molecule. The invention also provides nucleic acids and cells useful in producing the proteins and methods for their use.